 CAMBRIDGE, Mass.--BUSINESS WIRE--- SAGE Sage--Sage Therapeutics NASDAQ: SAGE, a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating brain disorders, today announced that, as part of the Companys plan to accelerate growth and leverage the talents of the leaders in the brain health space, Barry Greene has been appointed chief executive officer. Mr. Greene, who most recently served as president of Alnylam Pharmaceuticals, 